Active Ingredient(s):Cariprazine FDA Approved: * September 17, 2015 Pharm Company: *FOREST LABS LLC Category:Antipsychotic
Cariprazine, sold under the brand names Vraylar in the United States and Reagila in the European Union, is an atypical antipsychotic which is used in the treatment of schizophrenia, bipolar mania, and bipolar depression. It acts primarily as a D3 receptor and D2 receptor partial agonist, with high selectivity for the D3 receptor. Positive Phase III study results were published for schizophrenia and mania in early 2012, and for bipolar d...
* May have multiple approval dates, manufacturers, or labelers. 3 Discussions